Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer

The goal of this clinical trial is to learn if drug regimen weekly paclitaxel/nab-paclitaxel, pembrolizumab, and mirabegron works to treat relapsed ovarian cancer in adults. It will also learn about the safety of the drug regimen. The main questions it aims to answer are: i) Does drug weekly paclitaxel/nab-paclitaxel, pembrolizumab, and mirabegron reduce tumor volume? ii) What medical problems do participants have when taking drug weekly paclitaxel/nab-paclitaxel, pembrolizumab, and mirabegron? Participants will: i) Take drug paclitaxel/nab-paclitaxel every week and pembrolizumab every 21 d

Trial Details

NCT ID
NCT07261683
Phase
PHASE2
Sponsor
Obstetrics & Gynecology Hospital of Fudan University
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Has provided documented informed consent for the study.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Has histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
  • Has received a front line platinum-based regimen (administered via either intravenous or intraperitoneal route) per local standard of care or treat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →